Merdad Parsey
Chief Tech/Sci/R&D Officer en GILEAD SCIENCES, INC. .
Fortuna: 7 M $ al 29/02/2024
Perfil
El Dr. Merdad V. Parsey es director independiente de Arcus Biosciences, Inc. y director médico de Gilead Sciences, Inc. Forma parte del Consejo de Administración de Arcus Biosciences, Inc. y de Sagimet Biosciences, Inc. Anteriormente, el Dr. Parsey trabajó como Director Médico Senior en Regeneron Pharmaceuticals, Inc., como Director Senior-Grupo Médico en Genentech, Inc., como Director Médico Asociado en Merck & Co., Inc., como Director-Medicina de Cuidados Críticos en la Facultad de Medicina de la Universidad de Nueva York, como miembro del Grupo Roche y como Director Médico Senior en Sunovion Pharmaceuticals, Inc. Se doctoró en la Universidad de Maryland.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
GILEAD SCIENCES, INC.
0.01% | 10/03/2024 | 98 304 ( 0.01% ) | 7 M $ | 29/02/2024 |
18/07/2023 | 12 794 ( 0.06% ) | 78 427 $ | 29/02/2024 |
Cargos activos de Merdad Parsey
Empresas | Cargo | Inicio |
---|---|---|
SAGIMET BIOSCIENCES INC. | Director/Board Member | 30/09/2010 |
GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/11/2019 |
ARCUS BIOSCIENCES, INC. | Director/Board Member | 13/07/2020 |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Director/Board Member | - |
Antiguos cargos conocidos de Merdad Parsey.
Empresas | Cargo | Fin |
---|---|---|
REGENERON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2004 |
New York University School of Medicine | Corporate Officer/Principal | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Chief Tech/Sci/R&D Officer | - |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Formación de Merdad Parsey.
University of Maryland | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 5 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
REGENERON PHARMACEUTICALS, INC. | Health Technology |
SAGIMET BIOSCIENCES INC. | Health Technology |
ARCUS BIOSCIENCES, INC. | Health Technology |
Empresas privadas | 4 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |